Answers are grounded in this paper and cite their sources.
Brain metastases are a major clinical challenge, as up to 40% of patients with metastatic cancer develop symptomatic brain metastases during their clinical course of disease [ 1 , 2 ]. Lung cancer, followed by breast cancer and melanoma, are the most frequent underlying histologies. However, other histologies like renal carcinoma and colorectal cancer were shown to present, with rising incidences of symptomatic brain metastases in the last decade [ 3 ]. Local therapies are currently still the main treatment backbone in patients with symptomatic brain metastases; however, the value of systemic targeted or immune-modulating therapies has increased, especially in patients with oligo- to asymptomatic disease [ 4 ]. Further, prevention of symptomatic brain metastases by targeted treatment has become a major field of interest, as brain metastases are frequently a life-limiting complication with an enormous impact on the quality of life [ 5 ].
No takes yet. Share an insight, caveat, or question.
Berghoff et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: